See more : Nagatanien Holdings Co.,Ltd. (2899.T) Income Statement Analysis – Financial Results
Complete financial analysis of 4D pharma plc (LBPSW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 4D pharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Tetra Bio-Pharma Inc. (TBP.TO) Income Statement Analysis – Financial Results
- Far Eastern International Bank Ltd. (2845.TW) Income Statement Analysis – Financial Results
- UV Flu Technologies, Inc. (UVFT) Income Statement Analysis – Financial Results
- National Standard (India) Limited (NATIONSTD.BO) Income Statement Analysis – Financial Results
- Boom Logistics Limited (BOL.AX) Income Statement Analysis – Financial Results
4D pharma plc (LBPSW)
About 4D pharma plc
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease. It also develops immuno-oncology products comprising MRx0518, MRx0573, and MRx1299 for solid tumors, and MRx0518 for pancreatic cancer; respiratory products, such as MRx-4DP0004 for asthma and COVID-19; central nervous system products, including MRx0005 and MRx0029 for neurodegeneration; and platform products comprising vaccines and autoimmune. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.
Source: https://incomestatements.info
Category: Stock Reports